Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologymhn delgocitinib topical Coverage & Prior Auth | O…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.744

    Delgocitinib (Anzupgo) topical for chronic hand eczema

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.744 alerts

    Get alerted when Policy CP.PHAR.744 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and continuation criteria for topical delgocitinib (Anzupgo) for chronic hand eczema in eligible members covered by the payer.

    Policy Summary
    Payermhn
    PolicyDelgocitinib (Anzupgo) topical for chronic hand eczema
    Policy CodePolicy CP.PHAR.744
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionProvider must submit documentation (office notes, lab results, or other clinical information) supporting that the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 g/2 wksmaximum single-interval dispensing
    60 g/momaximum monthly dose
    ≥18minimum age for coverage
    12 moauthorization period
    ~10references

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    inv-01: Initial Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Initial CH E criteria: 1. Diagnosis of chronic hand eczema (CHE). 2. Hand eczema persisted >3 months or recurred ≥2 times within the last 12 months. 3. Provider attestation that member has moderate to severe hand eczema (see Appendix D). 4. Prescribed by or in consultation with a dermatologist or allergist. 5. Age ≥ 18 years. 6. Prior therapy requirements met (see Prior Therapy Requirements / Step Therapy node). 7. Anzupgo is not prescribed concurrently with biologic medications, biologic DMARDs, JAK inhibitors, or potent immunosuppressants. 8. Dose does not exceed both: (a) one 30-gram tube per 2 weeks; and (b) 60 grams per month.

    Prior authorization documentation required

    inv-02: Prior Therapy Requirements / Step Therapy — 1 top-level node

    Prior therapy options (state-dependent): Option A (Illinois HIM only): Failure of one formulary topical corticosteroid unless clinically significant adverse effects or contraindications. Option B (all other requests): Failure of both (i) one formulary topical corticosteroid used ≥2 weeks; and (ii) either a second formulary topical corticosteroid used ≥2 weeks OR one topical calcineurin inhibitor used ≥4 weeks (prior authorization may be required for topical calcineurin inhibitors).

    State-specific variation: Illinois HIM vs other requests

    inv-03: Continuation Therapy — Covered for continuation when ALL of the following are met:

    Covered for continuation when ALL of the following are met:

    Continuation therapy: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria; or (b) member is currently receiving medication and enrolled in a state/product with continuity of care regulations. 2. Member is responding positively to therapy as evidenced by reduction in symptoms and improvement in signs (e.g., decreased itching, erythema, scaling, hyperkeratosis/lichenification, vesiculation, edema, fissures). 3. Anzupgo is not prescribed concurrently with biologic medications, biologic DMARDs, JAK inhibitors, or potent immunosuppressants. 4. If request is for a dose increase, the new dose does not exceed both: (a) one 30-gram tube per 2 weeks; and (b) 60 grams per month.

    Approval duration: 12 months

    Non-FDA approved indications for delgocitinib (Anzupgo) topical are not authorized by this policy unless there is sufficient documentation of efficacy and safety consistent with the plan’s off-label use requirements. Providers should follow the referenced off-label use policies (CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or submit evidence of coverage documentation to support approval for an off-label indication.

    For Medicaid members, if a state Medicaid coverage provision conflicts with the coverage provisions in this clinical policy, the state Medicaid coverage provisions take precedence. Refer to the applicable state Medicaid manual for specific coverage requirements.

    Use of delgocitinib for diagnoses or indications not listed in this policy is not authorized without supporting evidence per the plan’s off-label use procedures. Requests for off-label use lacking documentation of efficacy and safety consistent with the referenced off-label policies may be considered not medically necessary and are not eligible for coverage.

    Coding and Product Availability

    Product NDC/AvailabilityNDC
    NDCDelgocitinib (Anzupgo) cream 2% in 30 g and 60 g tubes
    Dose limits
    Maximum single-interval dispensingOne 30-gram tube per 2 weeks
    Maximum monthly dose60 grams per month
    Dosing frequency for CHEApply a thin layer twice daily to affected hands and wrists

    Provider Actions and Prior Authorization

    Prior Authorization

    Obtain prior authorization and document all approval criteria

    Prior authorization is required and must demonstrate the member meets all policy criteria for chronic hand eczema, including diagnosis, disease duration/severity, prescriber specialty, age ≥ 18 years, prior topical therapy failure per the policy, and adherence to dosing limits (one 30‑g tube per 2 weeks; 60 g/month). Product availability (Anzupgo cream 2% in 30 g and 60 g tubes) is noted in the policy.

    • Show diagnosis of chronic hand eczema and duration (>3 months or ≥2 recurrences in 12 months).
    • Provide prescriber attestation of moderate to severe disease and that prescriber is a dermatologist or allergist (or in consultation).
    • Document prior topical therapy failures per policy (see step therapy node).
    • Confirm requested dose does not exceed one 30 g tube per 2 weeks and 60 g/month.
    Prior Authorization

    Follow payer prior authorization processes

    This clinical policy is intended as medical necessity guidance to assist coverage determinations; providers must follow the Health Plan's prior authorization processes and administrative procedures when submitting requests.

    Background

    Delgocitinib (Anzupgo) is a topical Janus kinase (JAK) inhibitor formulated as a 2% cream and is FDA-approved for adults with moderate to severe chronic hand eczema who have had an inadequate response to, or for whom topical corticosteroids are not advisable. The product is available in 30 g and 60 g tubes, and dosing in the approval criteria aligns with the trial and prescribing information recommendations.

    Definitions

    CHE (Chronic Hand Eczema) — definition and diagnostic thresholds
    Definition of CHEHand eczema that has persisted >3 months or returned two or more times within the last 12 months
    Required diagnosis documentationProvider attestation of chronic hand eczema and clinical course per policy criteria
    Prescriber/consult requirementPrescribed by or in consultation with a dermatologist or allergist
    Moderate to severe (IGA-CHE/PGA) — severity descriptors and surface area guidance
    Trial severity scale (IGA-CHE)Moderate to severe defined as IGA-CHE score 3–4 used in DELTA trials (at least one clearly perceptible or marked erythema, scaling, or hyperkeratosis/lichenification plus additional signs such as clustered vesicles, definite edema, or deep fissures)
    PGA surface area guidance — Moderate
    Policy Summary
    Payermhn
    PolicyDelgocitinib (Anzupgo) topical for chronic hand eczema
    Policy CodePolicy CP.PHAR.744
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionProvider must submit documentation (office notes, lab results, or other clinical information) supporting that the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product AvailabilityProvider Actions and Prior AuthorizationBackgroundDefinitions
    • Follow the Health Plan's specific prior authorization forms, submission portals, and timelines.
    • Policy guidance does not guarantee payment; adhere to plan coverage documents.
    Step Therapy

    Meet step therapy prior topical treatment requirements

    Step therapy requires documented failure of specified topical corticosteroid regimens and/or a topical calcineurin inhibitor as detailed by state: Illinois HIM requests require failure of one formulary topical corticosteroid used ≥2 weeks; all other requests require failure of one formulary topical corticosteroid used ≥2 weeks plus either a second formulary topical corticosteroid used ≥2 weeks or one topical calcineurin inhibitor used ≥4 weeks, unless contraindicated or adverse effects occur.

    • Illinois HIM: failure of one formulary topical corticosteroid (≥2 weeks) unless contraindicated.
    • Other requests: failure of one formulary topical corticosteroid (≥2 weeks) AND either a second formulary topical corticosteroid (≥2 weeks) OR a topical calcineurin inhibitor (≥4 weeks).
    • Prior authorization may be required for topical calcineurin inhibitors.
    Step Therapy

    When step therapy is not specified, follow plan/state guidance

    The policy also notes that no explicit step therapy requirements are provided in some policy chunks; where step logic is not specified, follow the plan-specific prior authorization instructions and the state-specific criteria described elsewhere in the policy.

    • If step therapy details are unclear for a specific line of business, use the Health Plan's administrative guidance and applicable state addenda.
    Documentation Required

    Provide required clinical documentation with the request

    Submit supporting clinical documentation with the prior authorization request — e.g., office chart notes, test results, and other clinical information — that demonstrates the member meets each approval criterion.

    • Include documentation of diagnosis, symptom duration/recurrence, prescriber attestation of severity, prior topical therapy details (agents, durations, responses), and current dosing.
    • Attach consultation notes when prescribed in consultation with a specialist.
    Documentation Required

    Policy is guidance — apply professional judgment and follow plan rules

    Providers are expected to exercise professional medical judgment; this policy is guidance for medical necessity determinations and does not guarantee coverage or payment — documentation and decisions must align with plan coverage documents and legal/regulatory requirements.

    • Policy does not replace provider clinical judgment or plan contract terms.
    • Ensure documentation aligns with applicable laws, regulations, and the Health Plan's coverage documents.
    Denial Risk

    Denial risk if criteria, prior therapy, specialty, age, or dosing limits not met

    Requests that fail to meet the documented criteria — including missing/incorrect diagnosis, lack of required prior topical therapy failure, prescriber not a dermatologist/allergist or lacking consultation, age <18, or exceeding dosing limits — may be denied.

    • Denial risks include non-FDA indications without off-label documentation and failure to meet continuity/continuation requirements for renewals.
    • Exceeding dose limits (more than one 30 g tube per 2 weeks or >60 g/month) can result in denial.
    Note

    Coverage is conditional on plan documents, state/federal law

    Coverage and benefit administration are subject to the Health Plan's coverage documents, applicable state and federal requirements, and legal regulations; where conflicts exist, law/regulation and plan documents govern.

    • For Medicaid members, state Medicaid provisions take precedence where they conflict with this clinical policy.
    • This policy does not constitute a contract or guarantee of payment.
    Two or more mild-to-moderate skin changes involving 10% to 30% of hand surface
    PGA surface area guidance — SevereTwo or more moderate-to-severe skin changes involving >30% of hand surface
    Anzupgo Prescribing Information — Manufacturer's prescribing information
    Manufacturer referenceAnzupgo Prescribing Information. LEO Pharma Inc.; July 2025. Available at FDA label URL
    Document typePrescribing information for delgocitinib (Anzupgo) cited in references
    Use in policyPrescribing information used as source for dosing and product availability
    DELTA trials — Phase 3 DELTA 1 and DELTA 2 trial references
    Primary Phase 3 trialsDELTA 1 and DELTA 2: multicenter, randomized, controlled, double-blind phase 3 trials of delgocitinib cream in adults with moderate to severe chronic hand eczema
    Severity assessment usedTrials utilized the Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) to enroll participants (score 3 or 4)
    Key publicationsLancet 2024 publication reporting DELTA 1 and DELTA 2 results (Bissonnette et al.) and DELTA 3 long-term extension in J Am Acad Dermatol 2025